Unknown

Dataset Information

0

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

ABSTRACT:

SUBMITTER: Zabriskie MS 

PROVIDER: S-EPMC4873472 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Zabriskie M S MS   Eide C A CA   Yan D D   Vellore N A NA   Pomicter A D AD   Savage S L SL   Druker B J BJ   Deininger M W MW   O'Hare T T  

Leukemia 20151119 6

Similar Datasets

Unknown New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.
| S-EPMC11497109 | biostudies-literature
Unknown RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
| S-EPMC8819354 | biostudies-literature
Unknown An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia.
| S-EPMC11312813 | biostudies-literature
Unknown A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210<sup>BCR-ABL1</sup> and P195<sup>BCR-ABL1</sup> isoforms.
| S-EPMC6278977 | biostudies-literature
Unknown In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia.
| S-EPMC8999266 | biostudies-literature
Unknown Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
| S-EPMC6893872 | biostudies-literature
Unknown Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.
| S-EPMC3156347 | biostudies-literature
Unknown Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia.
| S-EPMC10335939 | biostudies-literature
Unknown Philadelphia Chromosome-positive Acute Myeloid Leukemia With e1a3 <i>BCR-ABL1</i> Fusion Transcript.
| S-EPMC7566865 | biostudies-literature
Unknown BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.
| S-EPMC6803074 | biostudies-literature